Red blood cell osmotic fragility in chronically hemodialyzed patients - PubMed (original) (raw)
Clinical Trial
doi: 10.1159/000044878.
Affiliations
- PMID: 9453400
- DOI: 10.1159/000044878
Clinical Trial
Red blood cell osmotic fragility in chronically hemodialyzed patients
S G Wu et al. Nephron. 1998.
Abstract
Chronic renal failure induces anemia and a short erythrocyte life span. Red blood cell (RBC) osmotic fragility is the resistance of RBC hemolysis to osmotic changes that is used to evaluate RBC friability. To find the cause of shortened red cell survival in uremic patients, we evaluated the RBC osmotic fragility in 57 chronic hemodialyzed patients. Each patient had received 12 h of dialysis per week continuously prior to being enrolled in the study. Nineteen healthy volunteers served as a control group. Biochemistry, hemoglobin, electrolyte, osmolarity, beta2-microglobulin, and intact parathyroid hormone were examined before and after the dialysis session. To evaluate the osmotic fragility of RBC, blood samples were collected in heparinized test tubes. Fifty microliters of the RBC of each individual was then incubated in solutions containing a series of various concentrations of NaCl ranging from 0 to 0.6%. The concentration of NaCl at which 50% of RBCs were lysed was considered the median osmotic fragility (MOF). The results showed that the MOF was significantly greater in hemodialyzed patients before dialysis than in the control group (0.41 +/- 0.03 vs. 0.39 +/- 0.02%). The osmotic resistance to hemolysis was also recorded after dialysis (MOF 0.38 +/- 0.03%). Correlation analysis showed that the MOF was significantly correlated with urea nitrogen, serum osmolarity, and intact parathyroid hormone level. In addition, the osmotic fragility was higher in patients who had a predialysis intact parathyroid hormone level > 100 pg/dl. In conclusion, hemodialysis can improve the osmotic fragility. The mechanism underlying this improvement may be the removal of low molecular weight uremic toxins, resulting in normalization of serum osmolarity. Our results indicate that parathyroid hormone is probably a major factor influencing RBC osmotic fragility in chronic renal failure.
Similar articles
- Lack of relation between secondary hyperparathyroidism and red blood cell osmotic fragility in chronic renal failure.
Docci D, Turci F, Baldrati L. Docci D, et al. Nephron. 1985;41(3):241-5. doi: 10.1159/000183590. Nephron. 1985. PMID: 3840575 - Effect of dialysis on erythrocyte membrane of chronically hemodialyzed patients.
Ibrahim FF, Ghannam MM, Ali FM. Ibrahim FF, et al. Ren Fail. 2002 Nov;24(6):779-90. doi: 10.1081/jdi-120015680. Ren Fail. 2002. PMID: 12472200 Clinical Trial. - Osmotic fragility of erythrocytes, cell deformability and secondary hyperparathyroidism in uremic patients on maintenance hemodialysis.
Docci D, del Vecchio C, Salvi P, Turci F, Salvi G, Cenciotti L, Pretolani E. Docci D, et al. Clin Nephrol. 1985 Feb;23(2):68-73. Clin Nephrol. 1985. PMID: 3987101 - Theoretical Bases for the Role of Red Blood Cell Shape in the Regulation of Its Volume.
Svetina S. Svetina S. Front Physiol. 2020 Jun 9;11:544. doi: 10.3389/fphys.2020.00544. eCollection 2020. Front Physiol. 2020. PMID: 32581839 Free PMC article. Review.
Cited by
- The role of hyperosmotic stress in inflammation and disease.
Brocker C, Thompson DC, Vasiliou V. Brocker C, et al. Biomol Concepts. 2012 Aug;3(4):345-364. doi: 10.1515/bmc-2012-0001. Biomol Concepts. 2012. PMID: 22977648 Free PMC article. - Hypocalcemia-based prediction of hungry bone syndrome after parathyroidectomy in hemodialysis patients with refractory secondary hyperparathyroidism.
Yang G, Zha X, Mao H, Yu X, Wang N, Xing C. Yang G, et al. J Int Med Res. 2018 Dec;46(12):4985-4994. doi: 10.1177/0300060518788744. Epub 2018 Jul 31. J Int Med Res. 2018. PMID: 30064280 Free PMC article. - Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease.
Sonkar SK, Singh HP, Sonkar GK, Pandey S. Sonkar SK, et al. J Family Med Prim Care. 2018 Jul-Aug;7(4):815-818. doi: 10.4103/jfmpc.jfmpc_174_17. J Family Med Prim Care. 2018. PMID: 30234059 Free PMC article. - Iron Therapy in Chronic Kidney Disease: Days of Future Past.
Lee KH, Ho Y, Tarng DC. Lee KH, et al. Int J Mol Sci. 2021 Jan 20;22(3):1008. doi: 10.3390/ijms22031008. Int J Mol Sci. 2021. PMID: 33498292 Free PMC article. Review. - Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system.
Santoro D, Caccamo D, Lucisano S, Buemi M, Sebekova K, Teta D, De Nicola L. Santoro D, et al. Biomed Res Int. 2015;2015:145828. doi: 10.1155/2015/145828. Epub 2015 Apr 27. Biomed Res Int. 2015. PMID: 26000281 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical